About: http://data.cimple.eu/news-article/1cf934df18358002d4ad4d16fc5e882778e036fede48a33042a7a1a4

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/1cf934df18358002d4ad4d16fc5e882778e036fede48a33042a7a1a4 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The European Medicines Agency said Thursday it has recommended authorising the use of the anti-viral drug remdesivir to treat the new coronavirus. "Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU," the agency said. It said the recommendation still needs approval from the European Commission, which is due to make a decision in the coming week. At least two major US studies have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients. Washington authorised the emergency use of the medicine -- which was originally intended as a treatment for Ebola -- on May 1, followed by several Asian nations including Japan and South Korea. EMA's human medicines committee said it has recommended granting a conditional marketing authorisation to remdesivir for the treatment of COVID-19 in adults and adolescents from 12 years of age who are suffering pneumonia and require extra oxygen. It said its assessment was based mainly based on data from a study sponsored by the US National Institute of Allergy and Infectious Diseases (NIAID). The research, published in the leading journal the New England Journal of Medicine in May, showed that injections of remdesivir speeded patient recovery compared with a placebo. On average it reduced patients' hospital stays from 15 days to 11. One study published in The Lancet, however, found no "significant clinical benefit" from treating coronavirus patients with remdesivir. "Taking into consideration the available data, the agency considered that the balance of benefits and risks had been shown to be positive in patients with pneumonia requiring supplemental oxygen; i.e., the patients with severe disease," the Amsterdam-based EU agency said. smt/txw/gd
schema:headline	EU body recommends use of remdesivir to treat coronavirus
schema:mentions	Oxygen therapy European Commission European Medicines Agency New England Antiviral drug Placebo Remdesivir Medication National Institute of Allergy and Infectious Diseases The Lancet Asia Pneumonia Allergy University of Washington Ebola virus disease South Korea Japan European Union Severe acute respiratory syndrome coronavirus 2 Agencies of the European Union
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-06-25 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	81 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software